Royalty Report: Cancer, Drugs, Biotechnology – Collection: 369284

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 16

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 16

Primary Industries

  • Cancer
  • Drugs
  • Biotechnology
  • Therapeutic
  • Drug Discovery
  • Delivery
  • Disease
  • Pharmaceuticals
  • Medical
  • Vaccine
  • Diagnostic
  • Diagnostic Substances

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 369284

License Grant
University grants Licensee and its affiliated companies and exclusive License under the Licensed Patents and a non-exclusive license under the know-how in the field of use to make, have made, use, sell, offer to sell and import Licensed Products and perform Licensed Services in the Licensed Territory. If any affiliated company exercises rights under this Agreement, such affiliated company shall be bound by all terms and conditions of this Agreement, including but not limited to indemnity and insurance provisions and royalty payments. In addition, Licensee shall remain fully liable to University for all acts and obligations of affiliated company such that acts of the affiliated company shall be considered acts of the Licensee. Exclusive refers to Licensed Patents only. Know-how, data and other materials licensed are provided on a non-exclusive basis only.
License Property
Licensor Inventions related to 'Multiple Novel Androgen Receptor Variants as Biomarkers and Therapeutic Targets for Androgen Refractory Human Prostate Cancer' and 'Methods and Compositions Related to Prostate Cancer Therapeutics'.

Licensed Patent means (a) U.S. Provisional Patent Application Nos. 62/041,368, 61/124,359. 61/124,328, 61/114,153 International Patent Application No. PCT/US2009/02392 U.S. Patent Application No. 12/988,299, Canadian Patent Application No. 2,721,506 and European Patent Application No. 09733012.0 and the inventions disclosed and claimed therein

Technology related to the development of a companion diagnostic to determine the AR-V7 status of patients with castration-resistant prostate cancer (CRPC) for use with the Company’s lead product, galeterone, which is in development for the treatment of AR-V7 positive metastatic CRPC.

Field of Use
Inventions related to certain assays to identify androgen receptor variants for use as a companion diagnostic with galeterone.

Galeterone is a highly selective, multi-targeted, oral small molecule drug candidate that has advantages over existing prostate cancer therapies. Galeterone acts by disrupting the androgen receptor signaling pathway, which is the primary pathway that drives prostate cancer growth. The pathway is ordinarily activated by the binding of male hormones, or androgens, such as testosterone and the more potent androgen dihydrotestosterone, or DHT, to the ligand binding domain of androgen receptors in prostate cancer cells. Galeterone disrupts the activation of the pathway through multiple mechanisms of action.

Field of Use companion diagnostic for Galeterone (excluding commercial sale as research reagent).

IPSCIO Record ID: 27588

License Grant
The Licensor granted an exclusive worldwide license, with the right to sublicense, under certain patents and patent applications to make, have made, use, sell, offer to sell and import certain anti-androgen steroids including galeterone. In addition, the Licensor granted a first option to receive an exclusive license to its rights in certain improvements to the licensed products.
License Property
Galeterone, is a highly selective, multi-targeted, oral small molecule drug candidate that is believed to have advantages over existing prostate cancer therapies. Galeterone disrupts the activation of the pathway through multiple mechanisms of action inhibition of the enzyme CYP17, which blocks the synthesis of testosterone; androgen receptor antagonism, which blocks the binding of testosterone or DHT with the androgen receptor; and androgen receptor degradation, which reduces the amount of androgen receptor protein in the tumor cells. The license includes rights to a U.S. patent covering compositions and methods of use of a class of compounds encompassing galeterone, which expires in 2017.
Field of Use
The Licensee exercised their option and acquired exclusive rights to licensed improvements under three amendments to the license agreement. In March 2009, the license agreement was amended to grant an exclusive license to oral prodrugs of the licensed products. In April 2012, the license agreement was amended to grant an exclusive license to compositions and methods of inducing endoplasmic reticulum stress. In October 2013, the license agreement was amended to grant an exclusive license to a patent application directed to analogs of galeterone that disrupt androgen receptor signaling by degrading the androgen receptor.

The Licensee had administered galeterone to over 250 prostate cancer patients and healthy volunteers in Phase I and Phase II clinical trials. The plans for a Phase III clinical trial are for the first half of 2015.

IPSCIO Record ID: 1617

License Grant
The Company obtains an exclusive worldwide license to the Licensed Patents, probasin gene (PG) and to practice, use or sell the Licensed Processes from Canadian University.
License Property
Licensed Patents shall mean all patent applications respecting PG (a) International PCT Application Serial No. PCT CA 9300319 filed August 9, 1993 entitled DNA Sequences of Rat Probasin Gene; and (b) all patent applications respecting PG which may be filed from time to time by University pursuant to this Agreement.
Field of Use
Field of Use shall mean human gene therapy involving the transfer of genetic material into target mammalian cells in vitro or in vivo for the purpose of intercellular drug delivery and/or treatment of a disease or medical condition.

IPSCIO Record ID: 3954

License Grant
The Parties, one U.S. and the other Japanese, desire and intend to collaborate with respect to the Development and Commercialization of Products in the Field in the Territory.
License Property
Two pharmaceutical companies entered into a global agreement to develop and commercialize MDV3100, a investigational drug for the treatment of prostate cancer.  MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

MDV3100, a new generation of oral anti-androgen, which shows different pharmacological profiles from current anti-androgens, has been shown in preclinical studies to provide more complete suppression of the androgen receptor pathway than bicalutamide, the most commonly used anti-androgen. MDV3100 slows growth and induces cell death in bicalutamide-resistant cancers via three complementary actions – MDV3100 blocks testosterone binding to the androgen receptor, impedes movement of the androgen receptor to the nucleus of prostate cancer cells (nuclear translocation), and inhibits binding to DNA. Preclinical data published in Science earlier this year demonstrated that MDV3100 is superior to bicalutamide in each of these three actions.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 372110

License Grant
Seller sold the inventory of Irofulven API and Data to Buyer and granted Buyer a non-exclusive, worldwide license to use our putative Irofulven DRP® companion diagnostic to advance the development and commercialization of Irofulven and other Illudins (sesquiterpenes with anti-tumor properties produced by some mushrooms). Also agreed not to engage in any drug development program for Illudins or any of its analogues or any use thereof for a period of five (5) years.
License Property
Irofulven active pharmaceutical ingredients (“API”) is a unique DNA damaging agent, is a semi-synthetic sesquiterpene derivative of illudin S, a natural toxin isolated from the Jack O’lantern mushroom (Omphalotus illudens). A companion diagnostic to advance the development and commercialization of Irofulven and other Illudins (sesquiterpenes with anti-tumor properties produced by some mushrooms).

Irofulven has two primary anti-tumor mechanisms of action first, it produces bulky single strand DNA adducts that are only repairable by the transcription coupled nucleotide excision repair (TC-NER) pathway; and second, it stalls RNA polymerase II leading to transcription and cell cycle arrest and apoptosis.

Field of Use
Field of use is for the treatment of various cancers. The therapeutic candidate was formerly developed, between 1995 and 2007, in 41 different clinical trials, including through Phase 3 clinical trials, which demonstrated Irofulven’s single agent activity in a range of indications, including castration-resistance prostate cancer (CRPC), ovarian, liver, and pancreatic cancer, and clinical activity in combination treatments targeting CRPC, colorectal and thyroid cancers.

Irofulven is a well-studied small molecule that causes bulky single strand DNA adducts that cause DNA damage in cancer cells, which can only be repaired by the transcription coupled nucleotide excision repair (TC-NER) pathway. This DNA modification stalls RNA polymerase II leading to transcription and cell cycle arrest and apoptosis in certain types of cancer cells.

IPSCIO Record ID: 362456

License Grant
University hereby grants to Israeli Licensee an exclusive license to make, have made, manufacture, provide, use, import, commercialize, distribute, offer for sale and sell the licensed product(s) in the United States and worldwide under the patent rights. This Grant shall apply to the Licensee and any affiliated company, except that any affiliated company shall not have the right to grant a sublicense to others as set forth. If any affiliated company exercises rights under this Agreement, such affiliated company shall be bound by all terms and conditions of this Agreement, including but not limited to indemnity and insurance provisions and royalty payments, which shall apply to the exercise of the rights, to the same extent as would apply had this Agreement been directly between University and the affiliated company. In addition, Licensee shall remain fully liable to University for all acts and obligations of affiliated company such that acts of the affiliated company shall be considered acts of the Licensee.
License Property
Patent Rights shall mean the (i) U.S. patent application, assigned to University entitled
“Discovery of Human miRNAs and Their Evaluation with a Dicer KO” and the invention disclosed and claimed therein, (ii) all continuations, divisions, and reissues based thereon, (iii) claims of continuation-in-part applications directed to subject matter specifically described in (i), (iv) any corresponding foreign patent applications, and (v) any U.S. patents, or foreign patents issuing, granted or registered on any of (i) through (iv).

Licensed Product)s) as used herein in either singular or plural shall mean any process or method, material, compositions, drug, or other product or service, the manufacture, use, provision or sale of which would constitute, but for the license granted to Licensee pursuant to this Agreement, an infringement of a valid claim of patent rights relating to a nucleic acid sequence (infringement shall include, but is not limited to, direct, contributory, or inducement to infringe).

Field of Use
Field of use is for diagnostic tests and therapies for many serious illnesses, including cancer and infectious diseases.

These diagnostic and therapeutic products relates to a discovered group of genes known as microRNAs. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA and are believed to play an important role in regulating protein production.

microRNAs have the potential to form the basis of a novel class of diagnostic tests and therapies for many serious illnesses, including cancer and infectious diseases.

IPSCIO Record ID: 330686

License Grant
The agreement grants rights to Licensee to patents and intellectual property, solely to develop, manufacture, exploit, import, use, offer for sale and sell Licensed Product and Licensed Process into and throughout the Territory for research and development of Companion Diagnostics.

Also included is a grant back If this Licensor desires to develop, manufacture, exploit, import, use, offer for sale or sell any Companion Diagnostic on its own or with or through any Affiliate or Third Party, it will send written notice thereof to Licensee, and, if Licensee chooses not to develop, then Licensor shall be granted any associated rights to do so.

License Property
The licensed technology includes (I) Alternative Splicing Event (ASE) technology based on International Patent Application WO 2012/116248 A1 entitled 'Alternatively Spliced mRNA Isoforms as Prognostic and Therapeutic Tools for Metastatic Breast Cancer and Other Invasive/Metastatic Cancers'; and (ii) Technology and know-how stemming.

Companion Diagnostics means any diagnostic product or biomarker arising from work performed by Licensor pursuant to the terms of this Agreement or otherwise derived from or based in whole or in part on Licensees Intellectual Property.

Discovery Product means a pre-clinical Licensed Product identified through a Screening Assay which possesses desirable properties of a therapeutic or prophylactic agent for the treatment of a clinical condition based on in vitro studies.

Therapeutic Product means an agent with prophylactic or therapeutic activity for the prevention and/or treatment of cancer, developed, in whole or in part, from a Discovery Product and intended to be used, or is used, to treat cancer in humans.

Licensee Patent Rights include
– FGFR1/2 IIIc in NSCLC resistant to erlotinib.
– FGFRviii in glioblastoma.

MIT Patent Rights include
– Alternatively Spliced mRNA lsoforms as Prognostic Indicators for Metastatic Cancer.

Field of Use
Field means the use or intended use in treatment and/or prevention of cancer in humans, and shall include the use of any Licensed Product or Licensed Process in connection with the development of Companion Diagnostics.

Licensees therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer.

IPSCIO Record ID: 275831

License Grant
Licensor agrees to grant to the United Kingdom Licensee, pursuant to the License Agreement (i) a non-exclusive royalty-free license to develop the Licensed Product for any Indication under the Licensor Know-how and Licensor Patent as well as (ii) an exclusive, royalty-bearing license to conduct Commercialization Activities, including the right to sublicense, within the Licensee Territory for any Indication under the Licensor Patent, Licensor Know-how and the Licensed Trademark. In accordance with the Parties’ agreement to extend the licensed territory, the Parties agree that the License Agreement related to all Patents and Patent Applications Controlled by Licensor in the European Territory which Cover the Licensed Products shall be amended and incorporated herein by reference, to include all Patents and Patent Applications Controlled by Licensor in the Licensee Territory (the Licensor Patent).

Licensee and Licensor entered into the Original Collaboration and License Agreement which, among other things, provides for certain terms and conditions relating to the conduct of certain development activities for the purpose of obtaining Regulatory Approvals in the United States of America and its territories and possessions (“US”) and in the European Territory for the Initial Products in certain indications, including the ADT Indication and the PIN Indication, for Commercialization Activities by Licensee of the Licensed Product in the European Territory.

Licensee and Licensor have agreed to collaborate in the design of the Additional Phase III Study to gain Regulatory Approvals by the FDA and the EMEA, and to get input from the FDA on the protocol for the Additional Phase III Study to better ascertain the FDA’s commitment that the Additional Phase III Study will be sufficient to support Regulatory Approval in the US, assuming the study achieves the agreed upon efficacy endpoints and the product candidate is determined to be safe.

Licensor has sought from Licensee an Additional Milestone Payment in consideration of additional rights granted hereunder, including but not limited to expanding Licensee’s territory and co-promoting the Licensed Product in the ADT Indication in the US; and Licensee desires to effect payment in respect thereof.

License Property
Licensor Patent shall have the meaning prescribed to it in this First Amendment. For the avoidance of doubt, Licensor Patent, as defined herein, shall supersede the definition of Licensor Patent defined in the License Agreement. The list of the Licensor Patent identified are International Patents.

The Licensed Product shall mean Toremifene 80 mg for the prevention of bone fractures and serious side effects in men with prostate cancer on androgen deprivation therapy (ADT), identified in the License Agreement as being within the scope of the ADT Indication.

Toremifene 20 mg is in an ongoing pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia (PIN).

Additional Phase III Study – Phase III Clinical Study of toremifene 80mg for the ADT Indication be conducted by Licensor for the obtaining of Regulatory Approval in the ADT Indication in the US.

Toremifene is a selective estrogen receptor modulator, or SERM, developed by GTx as a daily tablet for the treatment of the multiple estrogen related side effects of androgen deprivation therapy for advanced prostate cancer and for the prevention of prostate cancer in high risk patients with High Grade Prostatic Intraepithelial Neoplasia lesions (HGPIN). Toremifene was designed to bind to and selectively modulate estrogen receptors depending on the tissue type.

Field of Use
This agreement pertains to the drug industry in the Field that shall have the meaning relating to the side effects of ADT in men with prostate cancer include among others bone fractures.

The development and commercialization of toremifene 80 mg is for the reduction of fractures in men with advanced prostate cancer on androgen deprivation therapy (ADT) and toremifene 20 mg is for the prevention of prostate cancer in high risk patients with High Grade Prostatic Intraepithelial Neoplasia lesions (HGPIN).

IPSCIO Record ID: 328126

License Grant
Licensor grants
–   an exclusive right and license in the Field to all of Licensors Intellectual Property, other than the MIT Patent Rights, solely to develop, manufacture, exploit, import, use, offer for sale and sell Licensed Product and Licensed Process into and throughout the Territory;
–   an exclusive right and sublicense to all of Licensors rights to the MIT Patent Rights under the Therapeutic License Agreement, subject to the Retained Rights, as that term is defined in the Therapeutic License Agreement as of the Effective Date, to develop, manufacture, exploit, import, use, offer for sale and sell Licensed Product and Licensed Process in the Field for use in the Territory; and
–   a non-exclusive license to all of Licensors Intellectual Property for research and development of Companion Diagnostics.

If at any time Licensee desires to develop, manufacture, exploit, import, use, offer for sale or sell any Companion Diagnostic on its own or with or through any Affiliate or Third Party, it will send written notice thereof to Licensor, and, if Licensor chooses not to develop, then Licensee shall be granted the rights to do so.

License Property
Licensors therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer.

The licensed technology includes (I) Alternative Splicing Event (ASE) technology based on International Patent Application WO 2012/116248 A1 entitled 'Alternatively Spliced mRNA Isoforms as Prognostic and Therapeutic Tools for Metastatic Breast Cancer and Other Invasive/Metastatic Cancers'; and (ii) Technology and know-how stemming.

Companion Diagnostics means any diagnostic product or biomarker arising from work performed by Licensee pursuant to the terms of this Agreement or otherwise derived from or based in whole or in part on Licensors Intellectual Property.

Discovery Product means a pre-clinical Licensed Product identified through a Screening Assay which possesses desirable properties of a therapeutic or prophylactic agent for the treatment of a clinical condition based on in vitro studies.

Licensor Patent Rights include
– FGFR1/2 IIIc in NSCLC resistant to erlotinib.
– FGFRviii in glioblastoma.

MIT Patent Rights include
– Alternatively Spliced mRNA lsoforms as Prognostic Indicators for Metastatic Cancer.

Field of Use
Field means the use or intended use in treatment and/or prevention of cancer in humans, and shall include the use of any Licensed Product or Licensed Process in connection with the development of Companion Diagnostics.

Licensee is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies.

IPSCIO Record ID: 245947

License Grant
The Foundation, not-for-profit academic medical center,  hereby grants to Licensee an exclusive license under the Licensed Rights to (a) make, have made, develop, use, import, export, distribute, market, promote, offer for sale and sell Products, (b) practice any method, process or procedure within the Licensed Patents or the Foundation Technology, and (c) otherwise exploit the Licensed Rights within the Licensed Territory for use within the Licensed Field; and to have any of the foregoing performed on its behalf by a third party.   The Parties have consented to the licensing of the Invention and Patent Rights under the License Agreement as amended by the terms set forth.
License Property
Patent Rights means all right, title and interest of the parties in, to and under any of the following
US Patent Number / Application    60/571,149
MDR Inhibitors which are the subject of the Patent Rights ('Invention').

Panacela Product shall mean the following Products developed and commercialized by Panacella
(i)   Arkil small-molecular polycyclic organic compound for systemic use to treat hormone-independent prostate tumors;
(ii)  Mobilan recombinant adenovirus of CBLB501 series for localized intratumor injection, converts the injected tumor into an efficient vaccine in situ by intratumor expression of a bacterial immunogen and its receptor; and

(iii)  Revercom nano-particle combining a chemotherapeutic drug with an inhibitor of the tumor drug resistance molecular mechanism of CBLC500 series for the treatment of tumors resistant to chemotherapy.

Foundation Technology shall mean all Foundation’s and Other Institution’s unpatented inventions, know-how, trade secrets, analysis, discoveries, techniques, methods, clinical and other data, and other intellectual property relating to the research of Doctor or arising out of or in direct connection with work of Doctor in the field of regulating cell death (i) curing cancer treatment side effects by differential modulation cell death / survival mechanisms uniquely deregulated in cancer cells; (ii) selective sensitization of cancer cells to treatment by using the same approach; (iii) using anti-apoptotic proteins secreted by microbial parasites to cure tissue damage associated with cancer treatment, inflammation and other pathologies (stroke, heart attack).

Field of Use
The Licensed Field means 0500 series modulating the androgen receptor (AR) pathway, constant activity of which is essential for growth and viability of the majority of prostate cancers, including those that have lost their dependence on androgen.

IPSCIO Record ID: 263763

License Grant
For the Compound and Product, the Licensor grants the Swiss Licensee an exclusive, sublicensable license in the Field in the Territory under Licensor Patent Rights, Licensor Know-How, Licensor Product Trademarks and Companion Diagnostic Trademarks to make, have made, use, offer to sell, sell, import and otherwise Develop and Commercialize Compound and Product.

Licensor grants to Licensee, to the extent Licensor is legally able to do so, a non-exclusive, sublicensable,  license in the Territory under such issued letters patent for Licensee to develop, make, have made, use, sell, offer for sale or import Compounds and Products in the Territory.

For the Covenants/Companion Diagnostic,  Licensor grants a non-exclusive license, with the right to grant sublicenses, under Licensor Patent Rights, Licensor Know-How, and Companion Diagnostic Trademarks to  market and promote the Companion Diagnostic in the Field in the Territory for use in connection with the Product and use the Companion Diagnostic in any way necessary or reasonably useful in order for Licensee to exercise the license granted by Licensor.

This agreement is to develop and commercialize a novel investigational therapeutic candidate vintafolide (EC145).

License Property
Vintafolide is a late-stage cancer drug candidate.

Vintafolide is a proprietary, injectable, conjugate consisting of folate (vitamin B9) linked to a potent vinca alkaloid chemotherapy agent, desacetylvinblastine monohydrazide (DAVLBH).

Etarfolatide is a folate-targeted molecular imaging agent that is being developed as a noninvasive method to identify tumors that over-express folate receptors.

Product(s) means any pharmaceutical or biological preparation.

Field of Use
Vintafolide is currently being evaluated in a Phase Ill clinical trial for platinum-resistant ovarian cancer, (PROCEED trial) and a Phase II trial for non-small cell lung cancer (NSCLC}; both studies are also using investigational companion diagnostic agent, etarfolatide (EC20).

Vintafolide is designed to preferentially target the chemotherapy agent to fast growing cancer cells that actively take up folate via the folate receptor. The folate receptor is expressed in a wide variety of cancers including ovarian, NSCLC, breast, colon and kidney.

IPSCIO Record ID: 372431

License Grant
The Parties, and others, entered into a settlement agreement to resolve litigation. Licensor became a party to the litigation after it entered into a license agreement with St. Jude Childrens Research Hospital, also a party in the litigation, for patent rights owned by St. Jude.

By this agreement, Licensee is obtaining a non-exclusive license to the Licensed Patents for use in the Field.

Licensor grants a non-exclusive sub license under the Licensed Patents for the Term of this Agreement to develop, have developed, make, have made, use, have used, import, offer for sale, have offered for sale, sell and have sold Licensed Products and Licensed Services.

License Property
Licensor is a biopharmaceutical company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer.

CART-19 shall mean a chimeric antigen receptor T cell directed against CD-19.

Penn Construct shall mean a CART-19 that includes a 4-1 BB signaling domain and a CD3s signaling domain.

Patent No. 8,399,645, titled 'Chimeric Receptors with 4-1BB Stimulatory Signaling Domain.'

Field of Use
Patent coves the technology for chimeric antigen receptors (CARs) used in cancer immunotherapies.

IPSCIO Record ID: 280840

License Grant
Licensor hereby grants to Licensee an exclusive license under the Licensed Patents in the Territory to make, have made, develop, use, practice, import, export, distribute, market, promote, offer for sale, and sell Licensed Products in the Licensed Field.

Licensor hereby grants to Licensee a non-exclusive license in the Territory under Licensor’s rights in the Know-How to use and practice any method, process, or procedure within the Know-How and otherwise use and exploit the Know-How; all in the Licensed Field; provided however, that with respect to Project Information, such non-exclusive license shall be limited to the Project Information Licensed Field.

License Property
The technology relates to drugs used in the treatment of various cancers.

Licensed Patents means
Patent Applications 61/249,596; 61/423,842; 61/423,825; 61/392,296; 61/423,832; 61/254,395; 61/423,838

1.
REVERCOM

·
Drug summary Liposome-packaged combination of proprietary molecule, inhibitor of multidrug resistance transporter, and conventional chemotherapeutic agent.

·
Potential use adjuvant applied as part of chemotherapy of cancer patients.

2.
MOBILAN

·
Drug summary Adenovirus-based treatment inducing immune response. Ready for final stage of preclinical development.

·
Potential use Universal anti-cancer vaccine.

3.
ARKIL

·
Drug summary Androgen receptor inhibitor, prepared for Hit-2-Lead optimization studies.

·
Potential use Nanodrugs for treatment of prostate cancer (both hormone (androgen)-dependent and –independent/refractory forms).

4.
ANTIMYCON

·
Drug summary MYC inhibitor.

·
Potential use Drugs for treatment of a broad range of solid tumors (breast, prostate, colon, non-small cell lung carcinoma, etc.) and hematological malignancies.

Projects and Licensed Patents
1. Projects

Drug
Definition

Mobilan = Research, development and support of an immunotherapeutic drug candidate based on recombinant adenovirus vector, stimulating immune response in humans as a vaccine-like treatment for cancer or other indications.

Revercom = Research, development, formulation and support of a drug candidate based on proprietary Reversan compound as an adjuvant for chemotherapy.

Antimycon = Research, development, lead optimization, formulation and support of a drug candidate regulating cMyc transcription factor for cancer indications.

Arkil = Research, development, lead optimization, formulation and support of a drug candidate regulating androgen receptor for prostate cancer.

Xenomycin = Research, development, lead optimization, formulation and support of a drug candidates based on proprietary Curaxin family of compounds for anti-infective/anti-biotic/anti-fungal applications.

2. Licensed Patents

Product
Title
Inventors
Country
Application No.
Patent No.

MOBILAN = Use of Toll-Like Receptor and Agonist for Treating Cancer
Andrei Gudkov (RPCI, CBLI)
U.S.
61/249,596
n/a

MOBILAN = Toll-like receptor 5 agonist produced and secreted by mammalian cells
Andrei Gudkov (RPCI), Venkatesh Natarajan (RPCI)
U.S.
61/423,842
n/a

MOBILAN = Functional bacreriophage-based nanoparticles coated by Toll-like receptor 5 agonist
Andrei Gudkov (RPCI, CBLI), Venkatesh Natarajan (RPCI)
U.S.
61/423,825
n/a

ANTIMYCON = Small molecules inhibiting oncoprotein MYC
Andrei Gudkov (RPCI), Catherine Burkhart (CBLI), Mikhail Nikiforov (RPCI), Michelle Haber (CCIA), Murray Norris (CCIA)
U.S.
61/392,296
n/a

ANTIMYCON = Small Molecules Inhibiting Oncoprotein MYC
Andrei Gudkov (RPCI), Catherine Burkhart (CBLI), Mikhail Nikiforov (RPCI), Michelle Haber (CCIA), Murray Norris (CCIA)
U.S.
61/423,832
n/a

ARKIL = Method for treating androgen receptor positive cancers
Katerina Gurova (RPCI), Natalia Narizhneva (CBL)
U.S.
61/254,395
n/a

REVERCOM = Dual cargo nanoparticles combining MRP1 inhibitors with chemotherapeutic drugs
Andrei Gudkov (RPCI, CBLI), Aridam Sen (RPCI), Catherine Burkhart (CBLI), Padmaja Kunapuli (RPCI)
U.S.
61/423,838
n/a

Field of Use
“Application” means the intended use for a Licensed Product, including the diagnosing, treating, curing, mitigating, and/or preventing a disease or other condition in a human or other animal, such as small cell lung cancer, large cell lung cancer, or other specific disease state.

IPSCIO Record ID: 344529

License Grant
By the original agreement, Licensor, a not-for-profit pediatric treatment and research facility, grants an exclusive license to develop, make, have made, use, import, offer for sale, sell, and have sold the Licensed Products and Licensed Services worldwide under the Patent Rights in the Licensed Field.
License Property
The licensed property is the invention(s) titled Chimeric Receptors with 4-1BB Stimulatory Signaling Domain.

This amendment #2 adds that Licensed Products shall mean, when used in relation to A Third Party Agreement, any material, cell, composition or drug, the manufacture, use, importation, offer for sale or sale of which would infringe any Valid Claim but for the license granted under the Third Party Sublicense Agreement. For the avoidance of doubt, as of the Third Party Sublicense Agreement. effective date, the Penn Construct and any product incorporating the Penn Construct are Licensed Products, and,

Adds that Licensed Services shall mean, when used in relation to the Third Party Sublicense Agreement, any service using a Licensed Product.

Penn Construct shall mean a CART-19 that includes a 4-1BB signaling domain and a CD3~ signaling domain.  CART-19 shall mean a chimeric antigen receptor T cell directed against CD 19.

Patent Rights are amended to read Patent Rights, when used in relation to the Third Party Sublicense Agreement, shall mean the patent and patent applications listed in the Third Party Sublicense Agreement;  and specifically exclude 7,435,596 and 8,026,097.

Field of Use
The shall mean all therapeutic, diagnostic, preventative and palliative uses.

Licensee is a biopharmaceutical company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Chimeric antigen receptor (CAR) recognize and kill cancer cells.

IPSCIO Record ID: 346459

License Grant
For the Sublicense to Licensed Patents, Licensor grants a non-exclusive sublicense under the Licensed Patents for the Term of this Agreement to develop, have developed, make, have made, use, have used, import, offer for sale, have offered for sale, sell and have sold Licensed Products and Licensed Services, in each case, in the Field in the Territory.
License Property
CART-19 shall mean a chimeric antigen receptor T cell directed against CD 19.

Licensed Patents shall mean Chimeric receptors with 4-1BB stimulatory signaling domain, and, shall specifically exclude 7,435,596 and 8,026,097 , and any other patent or patent application that claims priority to, or common priority with, or is a divisional, continuation, re-issue, renewal, reexamination, substitution or extension of any patent or patent application identified in clause (a) above that contains only claims directed to the expansion of natural killer NK cells.

Licensed Product shall mean any material, cell, composition or drug, the manufacture, use, importation, offer for sale or sale of which would infringe any Valid Claim but for the license granted under this Agreement. For the avoidance of doubt, as of the Effective Date, the Penn Construct and any product incorporating the Penn Construct are Licensed Products, as defined under this Agreement.

Penn Construct shall mean a CART- 19 that includes a 4-1BB signaling domain and a CD3~ signaling domain.

Licensor is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.

Field of Use
Patents cover the technology for chimeric antigen receptors (CARs) used in cancer immunotherapies.

IPSCIO Record ID: 6345

License Grant
The Company grants an exclusive, worldwide, royalty-bearing License, with the right to subLicense, to make, have made, use, sell and import Licensed Products, which includes finished products used for the detection of the Company’s proprietary prostate cancer biomarkers in both urine and biopsied prostate tissue for differentiating clinically significant prostate cancer from other prostate conditions, and to use Patent Rights and Know-How covering the prostate cancer biomarkers.
License Property
Licensed Product(s) shall mean finished products consisting of one or more nucleic acid detection reagents for the assay of one or more Prostate Marker(s) for use in the Field, the manufacture, use, sale or importation of which, but for the rights granted herein, would infringe a Valid Claim within Patent Rights.

U.S.
7,117,188
Method of Identifying Patterns in Biological Systems and Uses Thereof

U.S.
12/025,724
Biomarkers Upregulated in Prostate Cancer

U.S.
12/242,264
Biomarkers Overexpressed in Prostate Cancer

U.S.
12/327,823
Methods for Screening, Predicting and Monitoring Prostate Cancer

U.S.
12/349,437
Methods for Screening, Predicting and Monitoring Prostate Cancer

Field of Use
Field shall mean the use of a molecular diagnostic assay using the Licensed Prostate Markers in in vitro diagnostics relating to prostate cancer, including the detection of the presence or risk of prostate cancer, or the selection of therapy, or in a Research Application related to prostate cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.